Last reviewed · How we verify

NCT03141944: IMPACT

Evolution of Hypodopaminergic Syndrome in Early Parkinson's Disease

Completed Last updated 29 March 2021
What this trial tests

trial testing Starkstein scale of Apathy in Parkinson Disease in 90 participants. Completed in 11 March 2020.

Timeline
23 February 2017
Primary endpoint
11 March 2020
11 March 2020

Quick facts

Lead sponsorUniversity Hospital, Grenoble
StatusCompleted
Study typeOBSERVATIONAL
Enrollment90
Start date23 February 2017
Primary completion11 March 2020
Estimated completion11 March 2020
Sites4 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Grenoble

Who can join

Adults 33 to 72, any sex, with Parkinson Disease or Apathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to describe the evolution of hypodopaminergic syndrome in patients with Parkinson's disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Improvement of apathy in early Parkinson's disease.
    Castrioto A, Schmitt E, Anheim M, Meoni S, et al · · 2025 · cited 1× · PMID 40274806 · DOI 10.1038/s41531-025-00937-w

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

Other University Hospital, Grenoble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03141944.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing